Dato-DXd for Pharmacists: Clinical Insights

If datopotamab deruxtecan (Dato-DXd) is approved for first-line metastatic TNBC, it could significantly influence clinical practice by providing an effective option for patients, particularly those ineligible for immunotherapy or with PD-L1–negative disease. Clinicians may incorporate Dato-DXd as a preferred first-line therapy, potentially shifting treatment sequencing and optimizing patient outcomes. Successful integration will rely heavily on interdisciplinary collaboration. Effective communication across the team, alongside proactive monitoring for toxicities such as neutropenia, gastrointestinal effects, and interstitial lung disease, is essential. This collaborative approach ensures safe, effective, and personalized delivery of Dato-DXd in routine clinical practice.